Alison J. Moskowitz

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett et al. · Blood · 2017 · 320 citations · Full text

Medicine, Hematology, Oncology +15

Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma

Craig H. Moskowitz, Matthew J. Matasar, Andrew D. Zelenetz et al. · Blood · 2011 · 284 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Steven M. Horwitz, Raphael Koch, Pierluigi Porcu et al. · Blood · 2017 · 283 citations · Full text

Medicine, Oncology, Pharmacology +7

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Alison J. Moskowitz, Heiko Schöder, Joachim Yahalom et al. · The Lancet Oncology · 2015 · 266 citations

Medicine, Oncology, Pharmacology +17